Tarsus Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a commercial-stage biopharmaceutical company incorporated in Delaware in November 2016 and headquartered in Irvine, California. The company focuses on the development and commercialization of novel therapeutic candidates, starting with eye care. Its lead commercial product is XDEMVY® (lotilaner ophthalmic solution) 0.25%, which is FDA-approved in the United States for the treatment of Demodex blepharitis, a common eyelid disease caused by Demodex mite infestation. Tarsus is also advancing a pipeline of category-creating programs based on its active pharmaceutical ingredient, lotilaner, including TP-04 (an ophthalmic gel in Phase 2 clinical trials for ocular rosacea) and TP-05 (an oral tablet in Phase 2 clinical trials for Lyme disease prevention).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercial adoption of XDEMVY in the U.S. by expanding the sales force with 15 to 20 Key Account Leaders to deepen engagement with core eye care professionals (ECPs) and driving patient activation through targeted direct-to-consumer (DTC) marketing campaigns.
Expected impact: Aims to drive weekly prescribing depth among the 15,000 core targeted ECPs, increase weekly refill rates toward a steady-state of 20%, and support the long-term peak U.S. sales target of over $2 billion.
Expanding the global footprint of TP-03 through strategic out-licensing and regulatory filings in major international markets, including Greater China, Europe, and Japan.
Expected impact: Securing regulatory approvals and commercial launches in international territories to generate milestone payments and high-margin tiered royalties.
Advancing the clinical development of lotilaner-based pipeline candidates, specifically TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis, to diversify the company's portfolio beyond its single commercial product.
Expected impact: Establishing clinical proof-of-concept for two major indications, significantly expanding the company's addressable market into dermatology and infectious disease prevention.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grand Pharma holds exclusive development and commercialization rights for TP-03 (XDEMVY) in the Greater China region (Mainland China, Hong Kong, Macau, and Taiwan). This partnership allows Tarsus to access the second-largest healthcare market in the world without incurring direct commercialization costs.
Terms: Tarsus received a $15 million milestone payment triggered by the NMPA approval in March 2026 and is eligible for additional regulatory milestones, sales-based milestones, and tiered royalties on net product sales in Greater China.
Elanco exclusively licensed the underlying lotilaner molecule to Tarsus for human health applications. This agreement forms the foundational intellectual property basis for XDEMVY, TP-03, TP-04, and TP-05.
Terms: Tarsus pays tiered royalties on U.S. net sales of XDEMVY (with certain U.S. royalty rights sold by Elanco to Blackstone in May 2025) and is subject to commercial and sales-based milestones, such as a $5 million milestone paid in September 2024 upon reaching $100 million in cumulative net sales.